TT may potentially suppress this evasion strategy in cells expressing wild-type MET, while tumours expressing exon 14 MET deletion mutants may be resistant to TT treatment, and this will require further analysis using exon 14 MET mutant cells. The gene discussed is MET; the disease is neoplasm.